Trial Profile

An Open-label, Randomised, Non-comparative Phase 2 Study Evaluating S 95005 (TAS-102) Plus Bevacizumab and Capecitabine Plus Bevacizumab in Patients With Previously Untreated Metastatic COlorectal Cancer Who Are Non-eligible for Intensive Therapy (TASCO1 Study)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 22 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bevacizumab (Primary) ; Tipiracil/trifluridine (Primary) ; Capecitabine
Indications Adenocarcinoma; Colorectal cancer
Focus Therapeutic Use
Acronyms TASCO1
Sponsors Servier

19 Apr 2022 Results of final overall survival, published in the British Journal of Cancer
17 Jan 2021 Result assessing final end-of-study analysis on the overall survival (OS) presented at the 2021 Gastrointestinal Cancers Symposium.
16 Jan 2021 Updated results presented in the Servier Media Release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com